Lenvatinib
Sign in to save this workspacePrimary targets: FLT1_VEGFR1, FLT4_VEGFR3, KDR_VEGFR2, RET · FDA status: FDA Approved
Selectivity scorecard
KISS
97.74
Gini
0.726
CATDS
0.020
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Lenvatinib. Strongest target: RET at 98.8% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | RET | 98.8% | 1.2% |
| 2 | KDR_VEGFR2 | 98.1% | 1.9% |
| 3 | FLT4_VEGFR3 | 97.4% | 2.6% |
| 4 | TNIK | 97.2% | 2.8% |
| 5 | FLT1_VEGFR1 | 94.8% | 5.2% |
| 6 | DDR2 | 94.3% | 5.7% |
| 7 | LCK | 93.4% | 6.6% |
| 8 | DDR1 | 92.3% | 7.7% |
| 9 | RIPK3 | 90.6% | 9.4% |
| 10 | PDGFRA | 88.0% | 12.0% |
| 11 | P38A_MAPK14 | 87.1% | 12.9% |
| 12 | C_KIT | 86.3% | 13.7% |
| 13 | FGFR1 | 85.5% | 14.5% |
| 14 | FGFR2 | 85.4% | 14.6% |
| 15 | FMS | 84.9% | 15.1% |
| 16 | FGFR3 | 79.9% | 20.1% |
| 17 | FGFR4 | 79.3% | 20.7% |
| 18 | MINK_MINK1 | 79.2% | 20.8% |
| 19 | SLK_STK2 | 77.1% | 22.9% |
| 20 | LYN | 76.6% | 23.4% |
Selectivity landscape
Where Lenvatinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Lenvatinib.
Annotations
Sign in to read and post annotations.
Loading…